EI
URGN icon

EAM Investors’s UroGen Pharma URGN Stock Holding History

EAM Investors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.92M Buy
+79,271
New +$2.15M 0.26% 158
2026
Q1 		– Sell
-160,412
Closed -$3.76M – 379
2025
Q4 		$3.76M Buy
+160,412
New +$3.48M 0.42% 126
2023
Q4 		– Sell
-170,523
Closed -$2.39M – 384
2023
Q3 		$2.39M Buy
+170,523
New +$2.74M 0.46% 70

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

EAM Investors's URGN Position: Q2 2026 in Review

EAM Investors opened a new position in UroGen Pharma (URGN) in Q2 2026: 79,271 shares worth $2.92M. The stake represents 0.26% of the portfolio and ranks #158 among its holdings. This is a return to the name: EAM Investors previously reported a position in URGN as recently as Q4 2025.

EAM Investors first reported a position in URGN in Q3 2023 and has held it in 3 quarters since. The position peaked at $3.76M in Q4 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • EAM Investors held 79,271 shares of UroGen Pharma worth $2.92M as of Q2 2026.
  • UroGen Pharma was a new EAM Investors position in Q2 2026.
  • UroGen Pharma made up 0.26% of EAM Investors's portfolio in Q2 2026, its #158 holding.
  • EAM Investors first reported a position in UroGen Pharma in Q3 2023 and has held it in 3 quarters since.
  • EAM Investors's UroGen Pharma position peaked at $3.76M in Q4 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.